KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 7/16/2013 |
| Start Date: | November 2011 |
A Multi-Center, Phase 3, Double-Blind, Randomized, and Controlled Trial of KD019 vs Erlotinib in Subjects With Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Progressed After First- or Second-Line Chemotherapy
This study involves treatment with KD019 or erlotinib in patients with Non-small cell lung
cancer (NSCLC) who have progressed after first- or second- line chemotherapy. It is
hypothesized that KD019 can prolong survival compared with erlotinib.
For Eligibility subjects must have:
- failed one or two previous courses of therapy.
- have no active brain metastasis. Treated non-active brain metastasis are acceptable.
- cannot have received an EGFR inhibitor (Tarceva[erlotinib] or Iressa[gefitinib]) in
the past.
- has demonstrated progressive disease.
We found this trial at
2
sites
Yale Cancer Center Yale Cancer Center combines a tradition of innovative cancer treatment and quality...
Click here to add this to my saved trials
Click here to add this to my saved trials